Tularik Receives Milestone Payment From Eli Lilly And Company

09-Nov-2001

Tularik Inc. (Nasdaq: TLRK) today announced that its anti-thrombotic research collaboration with Eli Lilly and Company (NYSE: LLY) has successfully progressed to an advanced stage of preclinical development, triggering an undisclosed milestone payment to Tularik.

As part of the July 2001 acquisition of the computer-aided molecular design (CAMD) unit of Protherics PLC, Tularik inherited all existing CAMD research agreements, including the anti-thrombotic research collaboration with Lilly. In addition, the acquisition included proprietary virtual screening and molecular modeling software and a team of software designers, computational chemists and medicinal chemists.

The multi-year Lilly collaboration was established to design and optimize inhibitors of Factor Xa using Tularik’s CAMD technology, as well as to investigate other potential anti-thrombotic targets. In addition to the current milestone payment, Tularik is entitled to additional payments for Factor Xa inhibitors as they progress through clinical trials to registration. Royalties are payable on sales of products emerging from the collaboration.

"The use of these capabilities in a successful collaboration with Lilly further demonstrates the value of our new, proprietary CAMD technology," remarked David V. Goeddel, Ph.D., Tularik’s CEO. "The acquisition of virtual screening capabilities is another example of Tularik’s strategy to apply novel technologies to augment and accelerate our small molecule drug discovery effort."

Factor Xa inhibitors are a new class of compounds targeting the blood-clotting process, with the aim of preventing or limiting clot formation. Blood clots cause serious and often fatal conditions, including heart attacks, strokes and deep vein thrombosis. Current therapies for these diseases rely mainly on injectable drugs, which have drawbacks in clinical usage. Over 10 million people worldwide are eligible to receive oral anticoagulants for the prevention and treatment of thrombotic diseases.

Other news from the department business & finance

These products might interest you

Limsophy

Limsophy by AAC Infotray

Optimise your laboratory processes with Limsophy LIMS

Seamless integration and process optimisation in laboratory data management

laboratory information management systems
ERP-Software GUS-OS Suite

ERP-Software GUS-OS Suite by GUS

Holistic ERP solution for companies in the process industry

Integrate all departments for seamless collaboration

software
LAUDA.LIVE

LAUDA.LIVE by LAUDA

LAUDA.LIVE - The digital platform for your device management

Comprehensive fleet management options for every LAUDA device - with and without IoT connectivity

laboratory software
ACD Spectrus Platform

ACD Spectrus Platform by ACD/Labs

Software for Analytical Data Handling in R&D

Standardized Analytical Data Processing & Knowledge Management

data management software
ZEISS ZEN core

ZEISS ZEN core by Carl Zeiss

ZEISS ZEN core - Your Software suite for connected microscopy in laboratory and production

The comprehensive solution for imaging, segmentation, data storage and analysis

microscopy software
Loading...

Most read news

More news from our other portals

So close that even
molecules turn red...